- Home
- ANL vs RGNX Comparison
ANL vs RGNX Comparison
Compare ANL & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | RGNX |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.5M | 418.1M |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ANL | RGNX |
|---|---|---|
| Price | $15.68 | $9.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $16.00 | ★ $28.75 |
| AVG Volume (30 Days) | 350.7K | ★ 570.9K |
| Earning Date | 04-20-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | N/A | $50.15 |
| Revenue Next Year | N/A | $23.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $0.88 | $5.85 |
| 52 Week High | $13.00 | $16.19 |
Technical Indicators
Market Signals| Indicator | ANL | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 80.26 | 57.11 |
| Support Level | $1.36 | $7.76 |
| Resistance Level | N/A | $10.08 |
| Average True Range (ATR) | 1.38 | 0.51 |
| MACD | 0.70 | 0.16 |
| Stochastic Oscillator | 99.31 | 95.65 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.